Early brain changes in people whose dream‑enacting sleep began or worsened after SSRI antidepressants
Official title: Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM sleep Behavior Disorder
Funded at University of Minnesota · NIH-11175319 · Data updated 2026-11-12
This project looks for early signs of brain degeneration in people who started acting out their dreams after beginning serotonergic antidepressants like SSRIs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $2,276,803 |
| NIH project number | 4RF1AG075101-03 |
| Project ID | NIH-11175319 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults whose dream‑enacting behaviors (REM sleep behavior disorder) began or worsened after starting a serotonergic antidepressant such as an SSRI are the main candidates for this work.
✕Less likely to help
People whose RBD has a clear non‑serotonergic cause, those already with advanced dementia, or those unwilling/unable to attend study visits or testing may not benefit from this project.
What this research studies
If your dream‑enacting behaviors began or got worse after starting an SSRI, the research team will study you to look for early signs of neurodegeneration. You may be asked to complete sleep recordings, tests of thinking and movement, color vision checks, and possibly brain imaging or other biomarker tests. The investigators will compare people with SSRI‑unmasked RBD to other RBD patients and to control participants to see whether the SSRI group already shows subtle cognitive, visual, or motor changes. Learning these patterns could help doctors spot who is at higher risk of developing Lewy body dementia or Parkinsonian disorders years before clear dementia appears.
Why it matters
Potential benefit: If successful, this work could help identify people at higher risk for Lewy body dementia or Parkinson's disease earlier so they can get closer monitoring, earlier care planning, or access to prevention trials.
How similar studies have gone: Previous research shows RBD often precedes Lewy body disorders and some early markers have been found, but using these methods specifically in SSRI‑unmasked RBD is relatively new.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Howell, Michael J — University of Minnesota
- Study coordinator: Howell, Michael J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain injuries affect sleep disorders in veterans
This study is looking at how brain injuries and PTSD might lead to sleep problems, specifically a condition called REM Sleep Behavior Disorder, in veterans, and it hopes to find out what causes these sleep issues and how they might relate to future health concerns.
-
Understanding early signs of neurodegeneration in patients with sleep behavior disorders
This study is looking at how REM sleep behavior disorder (RBD) might be linked to early signs of dementia in people who have started taking certain antidepressants, and it hopes to help identify warning signs like changes in color vision or mild memory issues that could mean a higher risk for conditions like Dementia w
-
Ginger as a Modifier of Ghrelin Levels in Parkinson’s Disease and REM Sleep Behavior Disorder
This study tests whether ginger capsules can raise ghrelin levels in people with Parkinson’s disease, REM sleep behavior disorder, and healthy controls.
-
Early PD signals in people with REM sleep behavior disorder
This study tests whether people with REM sleep behavior disorder show early signs of Parkinson’s disease before classic symptoms appear.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Multimodal prospective cohort of Parkinsonism
This project will try to track disease progression and improve diagnosis using imaging, clinical tests, and biological samples in people with parkinsonism, people with REM sleep behavior disorder, and healthy volunteers over five years.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.